Skip to content

In the BioHarmony Drug Report Database

Repaglinide

Prandin, NovoNorm (repaglinide) is a small molecule pharmaceutical. Repaglinide was first approved as Prandin on 1997-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against ATP-binding cassette sub-family C member 8.
Trade Name NovoNorm, Prandin
Common Name Repaglinide
Indication type 2 diabetes mellitus
Drug Class Antidiabetic, SGLT2 inhibitors, not phlorozin derivatives
Repaglinide
Get full access now